 "Ajanta Pharma gains on USFDA nod for Almotriptan Malate tablets")
The tablets are the generic version of Axert which are dispensed for the treatment of acute migraine pain relief. Ajanta Pharma USA Inc., a wholly-owned subsidiary of Ajanta Pharma Ltd, is scheduled to launch Almotriptan tables in US shortly, the company said in a release.
Till date, USFDA has granted Ajanta Pharma eight ANDA final approvals and two tentative approvals, the release added.
The stock opened at Rs 1,421 and touched a high of Rs 1,449. At 10am, over 74,000 shares were traded on both the stock exchanges.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%